From 28be216bde264ce86c6ebae80d5f9c8fb2ef2061 Mon Sep 17 00:00:00 2001 From: Teleo Agents Date: Sun, 15 Mar 2026 19:39:30 +0000 Subject: [PATCH 1/2] extract: 2025-11-06-trump-novo-lilly-glp1-price-deals-medicare Pentagon-Agent: Ganymede --- ...t cost impact inflationary through 2035.md | 6 ++++ ...just-clinical-factors-drive-persistence.md | 6 ++++ ...ion-from-supplement-to-dominant-program.md | 6 ++++ ...-novo-lilly-glp1-price-deals-medicare.json | 32 +++++++++++++++++++ ...mp-novo-lilly-glp1-price-deals-medicare.md | 18 ++++++++++- 5 files changed, 67 insertions(+), 1 deletion(-) create mode 100644 inbox/archive/.extraction-debug/2025-11-06-trump-novo-lilly-glp1-price-deals-medicare.json diff --git a/domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md b/domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md index 787d6d273..ce839be41 100644 --- a/domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md +++ b/domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md @@ -29,6 +29,12 @@ Real-world persistence data from 125,474 commercially insured patients shows the The Cell Press review characterizes GLP-1s as marking a 'system-level redefinition' of cardiometabolic management with 'ripple effects across healthcare costs, insurance models, food systems, long-term population health.' Obesity costs the US $400B+ annually, providing context for the scale of potential cost impact. The WHO issued conditional recommendations within 2 years of widespread adoption (December 2025), unusually fast for a major therapeutic category. + +### Additional Evidence (challenge) +*Source: [[2025-11-06-trump-novo-lilly-glp1-price-deals-medicare]] | Added: 2026-03-15* + +The November 2025 Medicare deal reduces GLP-1 prices to $245/month (82% below list) with $50/month out-of-pocket caps for eligible beneficiaries starting April 2026. However, eligibility is limited to ~10% of Medicare beneficiaries with specific comorbidities (BMI ≥27 + prediabetes/CVD, or BMI >30 + heart failure/hypertension/CKD). The narrow targeting may change the cost-effectiveness calculus: in high-risk patients with multiple comorbidities, the multi-organ protective effects could generate sufficient downstream savings to offset drug costs under capitated payment models, even if broader population-level impact remains inflationary. + --- Relevant Notes: diff --git a/domains/health/lower-income-patients-show-higher-glp-1-discontinuation-rates-suggesting-affordability-not-just-clinical-factors-drive-persistence.md b/domains/health/lower-income-patients-show-higher-glp-1-discontinuation-rates-suggesting-affordability-not-just-clinical-factors-drive-persistence.md index c8aa03417..d93f4068a 100644 --- a/domains/health/lower-income-patients-show-higher-glp-1-discontinuation-rates-suggesting-affordability-not-just-clinical-factors-drive-persistence.md +++ b/domains/health/lower-income-patients-show-higher-glp-1-discontinuation-rates-suggesting-affordability-not-just-clinical-factors-drive-persistence.md @@ -37,6 +37,12 @@ At $245/month list price, even modest copays ($50-100/month) create a sustained The source does not provide granular income-stratified discontinuation rates, so the magnitude of the effect is unclear. It's possible income is a proxy for other factors (health literacy, access to care coordination, baseline health status) rather than affordability per se. + +### Additional Evidence (confirm) +*Source: [[2025-11-06-trump-novo-lilly-glp1-price-deals-medicare]] | Added: 2026-03-15* + +The Medicare GLP-1 deal establishes $50/month out-of-pocket maximum for tirzepatide (Zepbound) starting April 2026, and $245/month pricing for Medicare/Medicaid patients generally. This represents an 82% reduction from ~$1,350/month list prices. The deal structure directly addresses the affordability barrier that drives discontinuation in lower-income populations, providing natural experiment conditions to test whether price reduction improves persistence rates in Medicare/Medicaid populations. + --- Relevant Notes: diff --git a/domains/health/medicare-advantage-crossed-majority-enrollment-in-2023-marking-structural-transformation-from-supplement-to-dominant-program.md b/domains/health/medicare-advantage-crossed-majority-enrollment-in-2023-marking-structural-transformation-from-supplement-to-dominant-program.md index 0f6a8d522..ac929d3ad 100644 --- a/domains/health/medicare-advantage-crossed-majority-enrollment-in-2023-marking-structural-transformation-from-supplement-to-dominant-program.md +++ b/domains/health/medicare-advantage-crossed-majority-enrollment-in-2023-marking-structural-transformation-from-supplement-to-dominant-program.md @@ -35,6 +35,12 @@ This is not a temporary shift. The 4% year-over-year growth (1.3M additional enr The Special Needs Plan growth is particularly significant: SNPs grew from 14% to 21% of MA enrollment in five years, with C-SNPs (chronic condition plans) growing 71% in 2024-2025 alone. This indicates MA is not just growing through healthier beneficiaries but expanding into higher-acuity populations. + +### Additional Evidence (extend) +*Source: [[2025-11-06-trump-novo-lilly-glp1-price-deals-medicare]] | Added: 2026-03-15* + +The Medicare GLP-1 coverage expansion creates a major test case for MA plan economics under capitation. The deal establishes $245/month pricing for Medicare patients, but the source notes that 'no clarity on whether the $245 price applies to MA plans or just traditional Medicare' and 'no details on how MA plans specifically will implement this.' Under capitation, MA plans bearing full risk would see the drug cost offset by downstream savings only if adherence is sustained in the high-risk comorbid population targeted by the narrow eligibility criteria. This creates divergent incentives between traditional Medicare (fee-for-service) and MA plans (capitated risk). + --- Relevant Notes: diff --git a/inbox/archive/.extraction-debug/2025-11-06-trump-novo-lilly-glp1-price-deals-medicare.json b/inbox/archive/.extraction-debug/2025-11-06-trump-novo-lilly-glp1-price-deals-medicare.json new file mode 100644 index 000000000..6f203bba9 --- /dev/null +++ b/inbox/archive/.extraction-debug/2025-11-06-trump-novo-lilly-glp1-price-deals-medicare.json @@ -0,0 +1,32 @@ +{ + "rejected_claims": [ + { + "filename": "medicare-glp-1-coverage-expansion-uses-manufacturer-price-concessions-to-bypass-cms-rulemaking.md", + "issues": [ + "missing_attribution_extractor" + ] + }, + { + "filename": "narrow-eligibility-criteria-for-medicare-glp-1-coverage-target-high-risk-patients-where-cost-savings-are-most-likely.md", + "issues": [ + "missing_attribution_extractor" + ] + } + ], + "validation_stats": { + "total": 2, + "kept": 0, + "fixed": 2, + "rejected": 2, + "fixes_applied": [ + "medicare-glp-1-coverage-expansion-uses-manufacturer-price-concessions-to-bypass-cms-rulemaking.md:set_created:2026-03-15", + "narrow-eligibility-criteria-for-medicare-glp-1-coverage-target-high-risk-patients-where-cost-savings-are-most-likely.md:set_created:2026-03-15" + ], + "rejections": [ + "medicare-glp-1-coverage-expansion-uses-manufacturer-price-concessions-to-bypass-cms-rulemaking.md:missing_attribution_extractor", + "narrow-eligibility-criteria-for-medicare-glp-1-coverage-target-high-risk-patients-where-cost-savings-are-most-likely.md:missing_attribution_extractor" + ] + }, + "model": "anthropic/claude-sonnet-4.5", + "date": "2026-03-15" +} \ No newline at end of file diff --git a/inbox/archive/2025-11-06-trump-novo-lilly-glp1-price-deals-medicare.md b/inbox/archive/2025-11-06-trump-novo-lilly-glp1-price-deals-medicare.md index 4b112ae56..b4642c6e2 100644 --- a/inbox/archive/2025-11-06-trump-novo-lilly-glp1-price-deals-medicare.md +++ b/inbox/archive/2025-11-06-trump-novo-lilly-glp1-price-deals-medicare.md @@ -7,9 +7,13 @@ date: 2025-11-06 domain: health secondary_domains: [internet-finance] format: news -status: unprocessed +status: enrichment priority: high tags: [glp-1, drug-pricing, medicare, policy, trump-administration, market-structure] +processed_by: vida +processed_date: 2026-03-15 +enrichments_applied: ["GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md", "lower-income-patients-show-higher-glp-1-discontinuation-rates-suggesting-affordability-not-just-clinical-factors-drive-persistence.md", "medicare-advantage-crossed-majority-enrollment-in-2023-marking-structural-transformation-from-supplement-to-dominant-program.md"] +extraction_model: "anthropic/claude-sonnet-4.5" --- ## Content @@ -45,3 +49,15 @@ On November 6, 2025, President Trump announced agreements with Eli Lilly and Nov PRIMARY CONNECTION: [[GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035]] WHY ARCHIVED: The price reduction + coverage expansion + narrow eligibility criteria fundamentally change the economics analyzed in the existing claim — the "inflationary through 2035" conclusion assumed higher prices and broader population EXTRACTION HINT: Focus on how narrow eligibility (comorbid patients only) changes the cost-effectiveness calculus vs. broad population coverage + + +## Key Facts +- Medicare/Medicaid GLP-1 price: $245/month (November 2025 deal) +- General TrumpRx price: $350/month (down from ~$1,350/month) +- Oral Wegovy: $149-$299/month (launching January 2026) +- Medicare beneficiary out-of-pocket cap for tirzepatide: $50/month (starting April 2026) +- Medicare GLP-1 payment demonstration starts July 2026 +- BALANCE Model in Medicaid starts May 2026 +- BALANCE Model in Medicare Part D starts January 2027 +- Estimated eligible Medicare population: ~10% of beneficiaries +- Eligibility: BMI ≥27 with prediabetes or CVD history, OR BMI >30 with heart failure, uncontrolled hypertension, or CKD -- 2.45.2 From f8aa846c6d8bb606e10733a8d1db0d7011b45855 Mon Sep 17 00:00:00 2001 From: Teleo Agents Date: Sun, 15 Mar 2026 19:40:52 +0000 Subject: [PATCH 2/2] auto-fix: strip 2 broken wiki links Pipeline auto-fixer: removed [[ ]] brackets from links that don't resolve to existing claims in the knowledge base. --- ...del makes the net cost impact inflationary through 2035.md | 4 ++-- 1 file changed, 2 insertions(+), 2 deletions(-) diff --git a/domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md b/domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md index ce839be41..3e162e477 100644 --- a/domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md +++ b/domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md @@ -19,13 +19,13 @@ The competitive dynamics (Lilly vs. Novo vs. generics post-2031) will drive pric ### Additional Evidence (extend) -*Source: [[2024-08-01-jmcp-glp1-persistence-adherence-commercial-populations]] | Added: 2026-03-15 | Extractor: anthropic/claude-sonnet-4.5* +*Source: 2024-08-01-jmcp-glp1-persistence-adherence-commercial-populations | Added: 2026-03-15 | Extractor: anthropic/claude-sonnet-4.5* Real-world persistence data from 125,474 commercially insured patients shows the chronic use model fails not because patients choose indefinite use, but because most cannot sustain it: only 32.3% of non-diabetic obesity patients remain on GLP-1s at one year, dropping to approximately 15% at two years. This creates a paradox for payer economics—the "inflationary chronic use" concern assumes sustained adherence, but the actual problem is insufficient persistence. Under capitation, payers pay for 12 months of therapy ($2,940 at $245/month) for patients who discontinue and regain weight, capturing net cost with no downstream savings from avoided complications. The economics only work if adherence is sustained AND the payer captures downstream benefits—with 85% discontinuing by two years, the downstream cardiovascular and metabolic savings that justify the cost never materialize for most patients. ### Additional Evidence (extend) -*Source: [[2025-06-01-cell-med-glp1-societal-implications-obesity]] | Added: 2026-03-15* +*Source: 2025-06-01-cell-med-glp1-societal-implications-obesity | Added: 2026-03-15* The Cell Press review characterizes GLP-1s as marking a 'system-level redefinition' of cardiometabolic management with 'ripple effects across healthcare costs, insurance models, food systems, long-term population health.' Obesity costs the US $400B+ annually, providing context for the scale of potential cost impact. The WHO issued conditional recommendations within 2 years of widespread adoption (December 2025), unusually fast for a major therapeutic category. -- 2.45.2